In one real-world study, patients on tirzepatide lost 15.3% of their body weight at 12 months, compared to 8.3% for those on semaglutide
Wilding JP, Batterham RL, Davies M, et al
Aspirin is one of the most commonly used medicines in the world
After six months, users lost 10.9% of total body weight and an average of 27.1 lbs (12.3 kg)
Compared with placebo, participants receiving semaglutide showed greater improvements across several alcohol-related outcomes
[19] United States [edit] In the United States, semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, [13] [14] and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease